-+ 0.00%
-+ 0.00%
-+ 0.00%

CSPC Group announced that the phase II clinical trial of the SYS6026 injection developed by the group to treat high-grade cervical squamous intraepithelial lesions associated with human papillomavirus type 16 or 18 has been officially launched in China. This product is a therapeutic mRNA vaccine. The registered category is therapeutic biological product class 1, and its target is HPV16 and 18 subtype E6 and E7 protein antigens. As a new non-surgical treatment option, this product is expected to provide new treatment options for HPV16 or type 18 related HSIL.

Zhitongcaijing·07/22/2026 13:09:10
Listen to the news
CSPC Group announced that the phase II clinical trial of SYS6026 injection developed by the group to treat high-grade cervical squamous intraepithelial lesions related to human papillomavirus type 16 or 18 has been officially launched in China. This product is a therapeutic mRNA vaccine. The registered category is therapeutic biological product class 1, and its target is HPV16 and 18 subtype E6 and E7 protein antigens. As a new non-surgical treatment option, this product is expected to provide new treatment options for HPV16 or type 18 related HSIL.